CRISPR and Metachromatic Leukodystrophy (MLD) | Wed. January 26, 2022 | 3:00 pm – 4:30 pm CET / 9:00 am – 10:30 am ET | Free CMN Live Webinar

CRISPR and Metachromatic Leukodystrophy (MLD)

A CRISPR-based approach to treat metachromatic leukodystrophy

Metachromatic leukodystrophy (MLD) is a rare autosomal recessive disease that arises from mutations in the ARSA gene, which encodes the Arylsulfatase A enzyme. Arylsulfatase A plays a key role in sulfatide (a type of fat) metabolism in brain cells, and its deficiency results in the accumulation of sulfatides in the brain. This leads to destruction of the protective myelin sheath, which surrounds the nerves in both the central nervous system and the peripheral nervous system. The resulting neurodegeneration leads to clinical manifestations that include halted or reduced motor and cognitive function. The disease may occur in different forms in infants, young persons and adults. All forms are progressive and result in premature death.

Current treatment options are by and large limited to symptom management and supportive care. Recently, researchers at the University of Tübingen, Germany, described a mutation-agnostic haematopoietic stem and progenitor cell (HSPC) gene therapy using CRISPR-Cas9 and an AAV repair template as a new potential treatment option for MLD. Their efforts led to efficient insertions and deletions and a high level of gene integration at the ARSA locus in human bone marrow–derived HSPCs, with no detectable off-target editing. They also demonstrated gene correction in HSPCs derived from two MLD patients with distinct mutations and demonstrated restoration of ARSA enzyme activity at levels similar to to healthy adults.

 

In this webinar, you will learn about:

  • Introduction about MLD and similar diseases
  • Cross correction as a therapeutic strategy for MLD
  • Ongoing pre-clinical work to develop a CRISPR-based gene therapy for MLD

 

Tentative Webinar Programme:

  • 15.00: Welcome and introduction by CRISPR Medicine News
  • 15.05: Justin S Antony PhD, Junior Group Leader at University Children’s Hospital, University of Tübingen, Germany - Presentation: Haematopoietic Stem Cell Gene Therapy for treating rare monogenic diseases related to the brain
  • 15.50: Q & A with Justin S Antony
  • 16.25: Close by CRISPR Medicine News

 

Speaker/Title:

Justin S Antony PhD, Junior Group Leader at University Children’s Hospital, University of Tübingen, Germany - "Haematopoietic Stem Cell Gene Therapy for treating rare monogenic diseases related to the brain".

Sign up to the Webinar

CRISPR and Metachromatic Leukodystrophy (MLD) | Wed. Jabuary 26, 2022 | 3:00 pm–4:30 pm CET / 9:00 am–10:30 am ET | Free CMN Live Webinar

 

Sorry - something went wrong, your inquiry has not been sent!!
Thanks for registering, more information will follow.

This webinar  is managed by CRISPR Medicine News (CMN). CMN is committed to protecting and respecting my privacy. CMN will guard my information responsibly and never share my email address.

By signing up, I authorise the webinar sponsors to contact me about their products. CRISPR Medicine News takes your privacy very seriously. We are able to produce and distribute this live webinar for free because of the kind support of our partners. To keep our live webinars free, we make the details you leave on the form available to Sponsors. As such, we use legitimate interest as the basis for processing your data. Our partners may contact you about their products and/or services.

We, CRISPR Medicine News, may also contact you regarding future webinars and other similar news and events that may interest you.

I may revoke my consent at any given time by sending an email to: sales@crisprmedicinenews.com

Speakers

Justin S Antony, Junior Group Leader at University Children’s Hospital, University of Tübingen, Germany

Justin S Antony, Junior Group Leader at University Children’s Hospital, University of Tübingen, Germany

Dr. Justin S Antony is a Junior Group Leader at the working group of Dr. Markus Mezger, University Children’s Hospital, University of Tübingen, Germany. Dr. Antony is a competitive advanced therapy scientist with a proven track record of success in both the biotech industry and academia. He is uniquely experienced in recent cutting-edge technologies including mRNA therapeutics, gene editing and gene therapy. Together with Dr. Mezger, part of his research focuses on the development of novel gene therapy modalities to treat rare genetic diseases, haemoglobinopathies, and cancer. Dr. Antony received his Bachelor’s degree from St. Xavier’s College, Palayamkottai, India and Master's degree from Bharathidasan University, India. Dr. Antony earned his Ph.D. from the University of Tübingen in the field of immunogenetics followed by postdoctoral research with Professor Michael Kormann at the University of Tübingen focused on mRNA therapeutics and gene editing. Dr. Antony holds both granted and pending patents and is a member of the American Society of cell and gene therapy network. He has published more than 25 research articles in peer-reviewed journals and received a handful of grants for his research.

CMN Webinar - CRISPR and Metachromatic Leukodystrophy (MLD)
CMN Webinar - CRISPR and Metachromatic Leukodystrophy (MLD)
Join WeDoCRISPR Channel on Discord
WeDoCRISPR Channel
CMN Webinars - Your Gateway to CRISPR Medicine

If you have any questions or request for webinars, please contact us at: sales@crisprmedicinenews.com

Future CMN Webinars will be listed here.

Always stay updated - Sign up to weekly newsletter.

CMN Articles - CRISPR and Rare Diseases

 

 

close
Search CRISPR Medicine